Abstract | BACKGROUND AND PURPOSE: PATIENTS AND METHODS: Men treated with PVP for symptomatic BPH between July 2002 and September 2003 who were receiving anticoagulants (N=24) were reviewed retrospectively. Their mean age was 75 years, and the mean prostate volume was 82 cc (range 34-164 cc). Nine men (38%) were in retention, eight (33%) had had a myocardial infarction, seven (29%) had had a cerebrovascular accident, and seven had peripheral vascular disease. Of these men, 8 were on warfarin, 2 on clopidogrel, and 14 on aspirin. Men on warfarin discontinued the drug 2 days prior to surgery and restarted it the day after. The other two drugs were not discontinued. The PVP was performed with an 80 W KTP side-firing laser (Laserscope Greenlight PV) through a 23F continuous-flow cystoscope with normal saline as the irrigant. RESULTS: The mean operative time was 101 minutes. No transfusions were required. Most (22; 92%) of the men were discharged without a catheter. The serum hematocrit did not change significantly (40.0% to 38.3%). The International Prostate Symptom Score decreased to 13.6, 10.9, 9.7, and 9.5 at 1, 3, 6, and 12 months from a mean of 18.7 preoperatively. The Qmax increased from 9.0 mL/sec preoperatively to 15.1, 16.3, 20.9, and 20.1 mL/sec at 1, 3, 6, and 12 months. No patients had clinically significant hematuria postoperatively, and none suffered clot retention. CONCLUSIONS:
|
Authors | Jaspreet S Sandhu, Casey K Ng, Ricardo R Gonzalez, Steven A Kaplan, Alexis E Te |
Journal | Journal of endourology
(J Endourol)
Vol. 19
Issue 10
Pg. 1196-8
(Dec 2005)
ISSN: 0892-7790 [Print] United States |
PMID | 16359214
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Aged
- Anticoagulants
(adverse effects, therapeutic use)
- Feasibility Studies
- Follow-Up Studies
- Hematocrit
- Hemorrhage
- Humans
- Laser Therapy
(methods)
- Male
- Prostatectomy
(methods)
- Prostatic Hyperplasia
(surgery)
- Retrospective Studies
- Severity of Illness Index
|